Clinical Trial · NCT05575440

Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET/CT in Patients With Differentiated Thyroid Cancer

Overview

This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.

Sponsor

Mayo Clinic

Phase

N/A

Contacts

Clinical Trials Referral Office

mayocliniccancerstudies@mayo.edu

855-776-0015

ClinicalTrials.gov

NCT05575440

Drug / Compound

Isotope(s):
Target(s):